ϟ
DOI: 10.1093/annonc/mdr261
¤ OpenAccess: Hybrid
This work has “Hybrid” OA status. This means it is free under an open license in a toll-access journal.
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
Mario Campone,Igor Bondarenko,Stephen Brincat,Yevhen Hotko,P.N. Munster,Ewa Chmielowska,P. Fumoleau,Robyn L. Ward,Nathalie Bardy-Bouxin,Eric Leip,Kathleen Turnbull,Charles Zacharchuk,Richard J. Epstein
Medicine
Bosutinib
Dasatinib
2012
Loading...
- MLA
- APA
- Chicago
- IEEE
- Harvard
- BibTeX
Cite this:
Generate Citation
“Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy” is a paper by Mario Campone Igor Bondarenko Stephen Brincat Yevhen Hotko P.N. Munster Ewa Chmielowska P. Fumoleau Robyn L. Ward Nathalie Bardy-Bouxin Eric Leip Kathleen Turnbull Charles Zacharchuk Richard J. Epstein published in 2012. It has an Open Access status of “hybrid”. You can read and download a PDF Full Text of this paper here.